← All indications
Bronchitis
Inflammation of the large airways in the lung including any part of the BRONCHI, from the PRIMARY BRONCHI to the TERTIARY BRONCHI.
Subtype terms (2)
More specific conditions that are subtypes of Bronchitis in the MeSH hierarchy.
- Bronchiolitis
48 drugs (38 approved, 10 experimental)
- Bronchitis, Chronic
70 drugs (58 approved, 12 experimental)
Drugs by status
Approved for this indication (5)
Phase 4 trials (24)
Phase 3 trials (25)
Phase 2 trials (16)
Phase 1 trials (2)
Organizations
Organization Involved with Phase 4 Indications (41)
- Adams Respiratory Therapeutics
- Merck
- Sanofi
- Zambon
- Bayer
- CPL Associates
- GlaxoSmithKline
- NeuTec Pharma
- Qingfeng Pharmaceutical Group
- Sunovion
- bene-Arzneimittel GmbH
- Ahn-Gook Pharmaceuticals Co.,Ltd
- Jordi Gol i Gurina Foundation
- The Netherlands Asthma Foundation
- National Heart, Lung, and Blood Institute (NHLBI)
- Guangzhou Medical University
- Katholieke Universiteit Leuven
- Johns Hopkins University
- Radboud University
- Sichuan University
- University of Milan
- Kecioren Education and Training Hospital
- Nanchang University
- University of British Columbia
- University of California, Los Angeles
- Gannan Medical University
- Jiujiang First People's Hospital
- First Hospital of Shijiazhuang City
- Medaimun GmbH
- Hanmi Pharmaceutical
- +11 more
Organization Involved with Phase 3 Indications (34)
- Abbott
- Grunenthal
- Novartis
- Engelhard Arzneimittel GmbH & Co.KG
- INC Research
- Inmunotek S.L.
- Korea United Pharm. Inc.
- Teva
- Daewon Pharmaceutical Co., Ltd.
- Replidyne
- Baqiyatallah Medical Sciences University
- Hanyang University
- Inje University
- Kyung Hee University
- Mahidol University
- McMaster University
- Unidad de Investigacion Medica en Epidemiologia Clinica
- Laval University
- University of Calgary
- Chung-Ang University
- University of Montreal
- Lee's Pharmaceutical
- Universidad Autonoma de Barcelona
- Yeungnam University
- Soonchunhyang University
- Ewha Womans University
- Isala Clinics, Zwolle, The Netherlands
- Hallym University
- Inha University
- University of Western Ontario
- +4 more
Organization Involved with Phase 2 Indications (19)
- Abgenix
- Vertex
- AstraZeneca
- EmeraMed
- Hanlim Pharm. Co., Ltd.
- Ionis Pharmaceuticals, Inc.
- North China Pharmaceutical Group Corporation
- PharmaKing
- Boehringer Ingelheim
- Syntara
- University of Michigan
- Wake Forest University
- Korea Pharmaceutical Manufacturers Association
- Mesoblast, Inc.
- Daejeon University
- Technical University of Dresden
- Yuhan Pharmaceutical Company
- Chinese Academy of Medical Sciences
- University Clermont Auvergne
Organization Involved with Phase 1 Indications (3)
Organization Involved with Other Experimental Indications (15)
- Minnesota Veterans Medical Research and Education Foundation
- Cystic Fibrosis Foundation Therapeutics
- University of Washington
- Kaiser Permanente
- University of Miami
- University of Oulu
- University of Virginia
- Wenzhou Medical University
- University of Colorado, Denver
- University of Minnesota
- Mercy Medical Group
- Department of Veteran Affairs
- Government of Kazakhstan
- Eurasia Invest Ltd., Kazakhstan
- Nazarbayev University Medical Center